세계의 면역글로불린 시장 보고서 : 제품, 용도, 전달 양식, 지역별(2024-2032년)

The global immunoglobulin market size reached US$ 15.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.

Also known as antibodies, immunoglobulins refer to a class of glycoprotein molecules produced by plasma or white blood cells (WBCs). They are generally present in the serum and cells of the immune system and function as antibodies by explicitly recognizing and binding antigens, such as bacteria or viruses, and aiding in their destruction. Their tests help doctors diagnose immunodeficiencies, allergies, and autoimmune conditions like juvenile idiopathic arthritis, lupus, and celiac disease. At present, different classes of immunoglobulins are available around the world depending on biological features, structure, target specificity, and distribution.

Immunoglobulin Market Trends:

Due to rapid urbanization and hectic schedules, there is a rise in the consumption of fast food among individuals. This, along with sedentary lifestyles and the increasing number of patients with medical conditions like multiple myeloma, Waldenstrom macroglobulinemia, and autoimmune disorders, represents one of the primary factors impelling the growth of the market. Additionally, rising awareness about early diagnosis and the increasing preferences for personalized medicines are contributing to market growth. Moreover, immunoglobulins through a variety of routes of administration help the body fight various infectious diseases. As a result, with the rising number of hospitalized patients with coronavirus disease (COVID-19) and an urgent need for effective therapies to prevent the spread of the pandemic, hyperimmune globulin is utilized as an effective medicine in managing the infection. Apart from this, several pharmaceutical companies are introducing new and advanced immunoglobulins with improved efficiency for the treatment of neurological disorders. Other factors, such as increasing funding for research and development (R&D) projects and the improving healthcare infrastructure are anticipated to propel the market growth further in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global immunoglobulin market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and mode of delivery.

Breakup by Product:

IgG

IgA

IgM

IgE

IgD

Breakup by Application:

Hypogammaglobulinemia

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Immunodeficiency Disease

Myasthenia Gravis

Others

Breakup by Mode of Delivery:

Intravenous Mode of Delivery

Subcutaneous Mode of Delivery

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADMA Biologics Inc., Baxter international Inc., Biotest AG, CSL Limited, Grifols S.A, Kedrion S.p.A, LFB SA, Octapharma AG, Sanquin Plasma Products B.V. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report

• 1. What was the size of the global immunoglobulin market in 2023?
• 2. What is the expected growth rate of the global immunoglobulin market during 2024-2032?
• 3. What are the key factors driving the global immunoglobulin market?
• 4. What has been the impact of COVID-19 on the global immunoglobulin market?
• 5. What is the breakup of the global immunoglobulin market based on the application?
• 6. What is the breakup of the global immunoglobulin market based on the mode of delivery?
• 7. What are the key regions in the global immunoglobulin market?
• 8. Who are the key players/companies in the global immunoglobulin market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Immunoglobulin Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 IgG
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 IgA
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 IgM
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 IgE
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 IgD
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Application

• 7.1 Hypogammaglobulinemia
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Immunodeficiency Disease
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Myasthenia Gravis
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Mode of Delivery

• 8.1 Intravenous Mode of Delivery
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Subcutaneous Mode of Delivery
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 ADMA Biologics Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Baxter international Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Biotest AG
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 CSL Limited
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Grifols S.A
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Kedrion S.p.A
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 LFB SA
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Octapharma AG
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 SWOT Analysis
  • 14.3.9 Sanquin Plasma Products B.V.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Takeda Pharmaceutical Company Limited
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis